Presentations -

Elucidation of IMiDs-resistant mechanism in multiple myeloma

Uozaki Ryo, Ichikawa Daiju, Matsushita Maiko, Hattori Yutaka

[Domestic presentation]  The 77th Annual Meeting of the Japanese Cancer Association (大阪市　大阪国際会議場) , 

2018.09

, 

Poster presentation, The 77th Annual Meeting of the Japanese Cancer Association

天然物コマロビキノン及び関連化合物の骨髄腫細胞に対する抗腫瘍活性の評価

HATTORI YUTAKA

日本薬学会第138年会 (金沢) , 

2018.03

, 

Oral presentation (general)

多発性骨髄腫治療薬による免疫原性細胞死の検討

HATTORI YUTAKA

第15回日本免疫治療学研究会学術集会 (東京) , 

2018.02

, 

Oral presentation (general)

Cereblon-independent anti-myeloma pathway of TC11, a novel compound of immunomodulatory drugs.

Misa Nakamura, Daiju Ichikawa, Shuji Aida, Nahoko Hashimoto, Wakana Murota, Ryo Uozaki, Mikio Okayama, Kota Fujimori, Yuko Yonemura, Noriko Tabata, Hiroshi Yanagawa, Maiko Matsushita, Yutaka Hattori.

[Domestic presentation]  第79回日本血液学会学術集会 (79th Annual Meeting) , 

2017.10

, 

Oral presentation (general), Japanese Society of Hematology

Evaluation of a novel therapeutic target in hematological malignancies. AACR special conference Tumor Immunology and Immunotherapy.

Matsushita M, Yokoe S, Ozawa K, Kanchi S, Ichikawa D, Matsuki E, Mori T, Okamoto　S, Hattori Y.

[International presentation]  AACR special conference Tumor Immunology and Immunotherapy (Boston) , 

2017.10

, 

Poster presentation, AACR

天然物由来の新規コマロビキノン誘導体はP53欠損多発性骨髄腫を克服する.

HATTORI YUTAKA

第76回日本癌学会学術総会 (横浜) , 

2017.09

, 

Oral presentation (general)

PEG(E)-TC11は、CRBN非依存的に細胞周期の調節を介してハイリスク骨髄腫の増殖を抑制する。

會田 宗司, 市川 大樹, 中村 美沙, 宇於崎 涼, 飯田 和樹, 穂積 暢史, 岡山 幹夫, 藤森 宏太, 米村 裕子, 田畠 典子, 山田 健人, 松下 麻衣子, 須貝 威, 柳川 弘志, 服部 豊

[Domestic presentation]  第42回日本骨髄腫学会学術集会, 

2017.05

, 

Oral presentation (general)

Establishment of KU-MEL9-specific cytotoxic T cells for the development of adoptive immunotherapy for multiple myeloma.

Yokoe S, Matsushita M, Ozawa K, Uchiumi A, Kashiwazaki S, Ichikawa D, Hattori Y

[International presentation]  The 8th International Symposium 2017. (Miyazaki) , 

2017.05

, 

Poster presentation, Japanese Society of Hematology

PEG(E)-TC11, a novel polyehylene glycol-linked phthalimide derivative, inhibited high-risk MM cell growth in vivo and in vitro via cell cycle G2/M arrest in a CRBN-independent manner.

Shuji Aida, Daiju Ichikawa, Kazuki Iida, Masashi Hozumi, MisaNakamura, Ryo Uozaki, Nahoko Hashimoto, Mikio Okayama, Yuko Yonemura,Noriko Tabata, Taketo Yamada, Maiko Matsushita, Takeshi Sugai, Hiroshi Yanagawa, Yutaka

[International presentation]  2017 Annual meeting of American Association for Cancer Research, 

2017.04

, 

Poster presentation

Komaroviquinone-derivatives, revealed anti-tumor effect on high-risk multiple myeloma cells in vitro as well as in vivo.

HATTORI YUTAKA

[International presentation]  58th AMERICAN SOCIETY of HEMATOLOGY Annual Meeting and Exposition., 

2016.12

, 

Poster presentation

Structural optimization and anti-tumor activities of komaroviquinone to high-risk myeloma.

HATTORI YUTAKA

[Domestic presentation]  第78回日本血液学会学術集会, 

2016.10

, 

Oral presentation (general)

Novel Komaroviquinone derivatives with anti-protosoal activity inhibited growth of high-risk myeloma cells in vivo.

HATTORI YUTAKA

[Domestic presentation]  第75回日本癌学会学術集会, 

2016.10

, 

Oral presentation (general), 日本癌学会

Drug Design for Overcoming High-Risk Myeloma and Identification of Novel Binding Proteins to Immune-Modulatory Drugs.

Hozumi M, Ichikawa D, Matsushita M, Kamiyama E, Yanagawa H, Tabata N, Kitabatake S, Ueda A, Yamaguchi T, Sato M, Hattori Y.

[International presentation]  57th American Society of Hematology, Annual Meeting and Exposition (Orlando, FL) , 

2015.12

, 

Oral presentation (general), American Society of Hematology

Clinical significance of 11;14 translocation in myeloma, AL amyloidosis and mantle cell lymphoma.

Kasuga M, Ikeda M, Shingaki S, Miyazaki K, Meshituka S, Yoshiki Y, Abe Y, Tsukada N, Hattori Y, Suzuki K.

[Domestic presentation]  第77回日本血液学会 (金沢) , 

2015.10

, 

Oral presentation (general), 日本血液学会

Identification of New IMiDs-Binding Proteins and Nonteratogenic Drug Design for High-Risk Myeloma.

Hozumi M, Matsushita M, Ichikawa D, Ozaki Y, Hasegawa Y, Terada F, Yanagawa H, Tabata N, Shiheido H, Oikawa T, Matsuo K, Yamada T, Wenlin Du W, Kitabatake S, Ueda A, Hattori Y.

[Domestic presentation]  第77回日本血液学会 (金沢) , 

2015.10

, 

Oral presentation (general), 日本血液学会

ハイリスク多発性骨髄腫に対する新規治療薬の開発

HATTORI YUTAKA

[Domestic presentation]  第16回 Pharmaco-Hematologyシンポジウム日本薬学会生物系薬学部会 (東京) , 

2015.06

, 

Oral presentation (general), 日本薬学会生物系薬学部会

白血病幹細胞に発現する新規がん精巣抗原の同定

HATTORI YUTAKA

[Domestic presentation]  第 12回日本免疫治療学研究会学術集会 (東京) , 

2015.02

, 

Oral presentation (general), 日本免疫治療学研究会

The clinical significance of decreasing CD138-positive myeloma cells in bone marrow.

Inoue J, Ikeda M, Shingaki S, Miyazaki K, Meshitsuka S, Abe Y, Tsukada N, Hattori Y, Suzuki K.

[Domestic presentation]  第76回日本血液学会 (大阪) , 

2014.11

, 

Oral presentation (general), 日本血液学会

Clinical and biological significance of codon 72 polymorphism of TP53 gene in multiple myeloma.

Hozumi M, Ikeda Y, Suzuki Y, Matsushita M, Ichikawa D, Hattori Y.

[Domestic presentation]  第76回日本血液学会 (大阪) , 

2014.10

, 

Oral presentation (general), 日本血液学会

Identification of novel cancer-testis antigen expressed in leukemic stem cells of chronic myelogenous leukemia.

〇Matsushita M, Nakamura M, Ichikawa D, Tsukamoto N, Kawakami Y, Hattori Y.

[International presentation]  43rd Annual Scientific Meeting of Society for Hematology and Stem Cells (Montreal, Canada) , 

2014.08